Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical School, shared Vivek Subbiah’s, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, post on LinkedIn, adding:
“Future. Is the word that comes to mind when you think of Vivek Subbiah, someone who does not wait for the future, but reads it, chases it, builds it.
Couldn’t be more appropriate to catch him in Chicago immediately before a meeting that will shape the future of oncology!”
Quoting Vivek Subbiah’s post:
“Great to catch up with an amazing friend and colleague Paolo Tarantino pre‑ASCO26 talking shop on the latest in ADC drug development, trips to Rome/Venice/Naples and much much more. Prepping my ADC talk for the Clinical Science symposium and realizing almost every other slide is one of his figures from his papers.
Nobody does ADC target visuals with more clarity and elegance OncoAlert, G Curigliano, Roberto Pestana, OncoDaily.”
Other articles Paolo Tarantino and Vivek Subbiah on OncoDaily.